Corvus Pharmaceuticals, Inc. (CRVS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Corvus Pharmaceuticals, Inc. (CRVS) is up 54.7% since the beginning of the year. At $12 per share, CRVS is trading 55.8% below its 52-week high of $27. Investors who bought $1,000 worth of CRVS shares 5 years ago would now be looking at an investment worth $4,362.

Corvus Pharmaceuticals, Inc. (CRVS) has returned 54.68% so far this year and 203.05% over the past 12 months. Over the last ten years, CRVS has returned -0.77% per year, falling short of the S&P 500 Index benchmark, which averaged 13.67% annually.

Based on dividend-adjusted daily data since Mar 23, 2016, CRVS's average daily return is +0.19%, while the average monthly return is +3.71%. At this rate, an investment would double in approximately 1.6 years.

Historically, 45% of months were positive and 55% were negative. The best month was May 2023 with a return of +181.5%, while the worst month was Apr 2017 at -52.2%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 10 months.

On a daily basis, CRVS closed higher 46% of trading days. The best single day was Jan 20, 2026 with a return of +166.0%, while the worst single day was Apr 4, 2017 at -50.0%.

Corvus Pharmaceuticals, Inc. has an annualized alpha of 39.77%, beta of 0.92, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since March 23, 2016.

• This stock participated in 168.00% of S&P 500 Index downside but only 106.96% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CRVS ranks 87 for risk / return — in the top 87% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Corvus Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Corvus Pharmaceuticals, Inc. was 96.97%, occurring on Mar 28, 2023. Recovery took 705 trading sessions.

The current Corvus Pharmaceuticals, Inc. drawdown is 53.33%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Corvus Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Corvus Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.